World Health Organization declared the COVID-19 outbreak a pandemic in 2020. Numerous explanations have been developed for this Comorbidity, such as immune system impairment due to abnormal production of adipokines and cytokines (eg, tumor necrosis factor-alpha and interferons),  as well as decreased phagocytic activity and chemotaxis among<unk> . These explanations justify the higher prevalence of COVID-19 among<unk> patients. Old age, male sex and some ethnic minority groups, such as Hispanic, Latino and African American, are considered as risk factors and are also related to worse outcome. There are some confirmed risk factors for<unk>  such as glycemic instability, immune deficiency and related comorbidities, like obesity and cardiac and renal disease. There are also some hypothesized risk factors such as reduced ACE2,  Increased furin and chronic inflammation. COVID-19 among<unk> patients has been related to higher rate of complications. Acute respiratory distress syndrome (ARDS), septic shock, acute kidney injury, acute heart injury and<unk> ketoacidosis are some of the frequently reported complications.<unk> patients with COVID-19 have higher rate of hospitalization, intensive care unit admission and death, compared to non-diabetics. These patients are presented with fever, cough, dyspnea, fatigue, chest pain, headache and some gastrointestinal complains. Concurrent COVID-19 and diabetes have been related to lower levels of lymphocytes, red blood cells (RBC), albumin and hemoglobin. Conversely, higher levels of neutrophils, erythrocyte sedimentation rate (ESR), D-dimer, interleukin-6 (IL-6) and interleukin-10 (IL-10) have been reported in these patients. Bilateral consolidation and ground‐glass opacification have been reported based on chest X-ray and CT scan, respectively. Insulin is used for hospitalized patients in order to maintain a desirable glycemic control and higher insulin requirements have been reported among<unk> patients. There are numerous considerations regarding antidiabetics and antihypertensive medications, their possible side effects and their effects on ACE2 expression. Hyperglycemia has been reported with lopinavir, ritonavir and glucocorticoids use. Furthermore, antivirals such as lopinavir and ritonavir should be used with caution with statin therapy due to augmented risk of hepatic and muscle toxicity.
COVID-19 in Diabetics
Nephrologic Disorders and COVID-19
COVID-19 x ray
COVID-19 non-medical therapy
Middle East respiratory syndrome coronavirus infection CT
COVID-19 differential diagnosis
Ebola laboratory tests
Rotavirus infection CT scan